Silver Book Fact

Fact image

Medicines in Development for Heart Disease and Stroke, 2008

PhRMA. 2008 Report: Medicines in Development for Older Americans; November 2008

Reference

Title
2008 Report: Medicines in Development for Older Americans
Publication Date
November 2008
Authors
PhRMA

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • Between 1980 and 2000, stroke mortality rates fell from 96.2 to 60.8 per 100,000 persons.  
  • Several prevention/early detection interventions for cardiovascular disease have cost-effectiveness ratios of $50,000-$70,000 per life saved.  
  • Treatment for hypertension using antihypertensive therapy has generated a benefit-to-cost ratio of at least 6:1.  
  • Between 1981 and 2004, death rates for heart disease and stroke declined by about 44%.